3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
6
CNS
3
Endocrine
2
Plasma cell
1
NET
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Wilms Tumor
6
Ovarian Neoplasms
6
Neuroblastoma
5
Testicular Neoplasms
4
Sarcoma
4
Prostatic Neoplasms
4
Osteosarcoma
4
Neuroectodermal Tumors, Primitive, Peripheral
4
Medulloblastoma
4
Kidney Neoplasms
4
Astrocytoma
4
Optic Nerve Glioma
3
Oligodendroglioma
3
Glioma
3
Familial ependymoma
3
Choroid Plexus Neoplasms
3
Central Nervous System Neoplasms
3
Testicular Germ Cell Tumor
2
Teratoma
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Ovarian Germ Cell Cancer
2
Neoplasms
2
Liver Neoplasms
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Pancreatic Neoplasms
1
Neuroectodermal Tumors
1
Interventions
pembrolizumab
23
Gemcitabine
14
Carboplatin
10
Nivolumab
9
Cyclophosphamide
9
olaparib
8
Specimen Handling
8
Paclitaxel
8
Trastuzumab
7
Magnetic Resonance Spectroscopy
6
fludarabine
5
Standard of Care
5
Irinotecan
5
Ipilimumab
5
Docetaxel
5
Cisplatin
5
Capecitabine
5
Biopsy
5
sargramostim
4
pertuzumab
4
palbociclib
4
enzalutamide
4
durvalumab
4
atezolizumab
4
aldesleukin
4
Taxes
4
Oxaliplatin
4
Fluorouracil
4
Erlotinib Hydrochloride
4
Early Intervention, Educational
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Temozolomide
×
Genitourinary
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled